Adding orally disintegrating selegiline (Zelapar) to patients taking dopamine agonists and experiencing complications
Phase of Trial: Phase IV
Latest Information Update: 13 Jul 2018
At a glance
- Drugs Selegiline (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 07 Dec 2008 Status changed from recruiting to completed, according to ClinicalTrials.gov.
- 30 Apr 2007 New trial record.